Jun 29, 2026 – 5.53pmThe clock is ticking on the sale of Healius’ clinical trials business Agilex Biolabs.Street Talk understands the $265 million market cap diagnostics company is targeting a signed deal by the time it delivers its full-year financial results in August.Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber?
PE, strategics line up for Healius’ Agilex as IMs hit inboxes
Sell-side adviser UBS issued more than 30 investment memorandums over the weekend and called for non-binding offers before the end of July.
TL;DRAI
Healius vende Agilex Biolabs (clinical trials) con valutazione $265M, firma attesa ad agosto al rilascio dei risultati annuali. PE e buyer strategici in competizione; consolidamento nel diagnostics riflette appetito M&A su business healthcare con asset data-sensitive.
136 words~1 min read
